UNSPSC 51141523: Paramethadione

This classification denotes an anticonvulsant agent with the molecular formula C7H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z615FRW64N, chemically known as 3,5-dimethyl-5-ethyloxazolidine-2,4-dione but generally known as paramethadione, which bears US NIH Compound Identifier 8280. European Medicines Agency schedules Paramethadione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09613MIG. The term PARAMETHADIONE is an International Non-Proprietary Name.

UNSPSC 51141523 Paramethadione, a Commodity code, does not align with recent state and local procurement activity tagged to it. The single recent opportunity — Seminole County, Florida's IFB 60459723LAS — solicits naloxone and safe drug deactivation systems, pharmaceutical harm-reduction products that fall outside paramethadione's narrow scope as an anticonvulsant medication. State and local procurement under this Commodity code shows no documented current activity in the targeted market.

Seminole County's IFB, posted June 30, 2026 with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement required vendors to include all shipping and delivery costs, comply with drug-free workplace certification and E-Verify requirements, and maintain workers' compensation, commercial general liability, and professional liability insurance. The contract structure included a two-year initial term with one-year renewal option and a three-month probationary period. While the opportunity is sourced under the paramethadione code, its actual commodity — harm-reduction medical devices — represents a data-tagging mismatch rather than authentic activity in anticonvulsant pharmaceutical procurement at the state and local level. Business development professionals tracking anticonvulsant drug supply chains should treat this code as inactive pending re-tagging or additional opportunities that reflect its actual scope.